First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom
RhoVac AB ("RhoVac") announces today, on January 7[th], 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac").The first patient in United Kingdom is enrolled in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment. The clinical phase